Result of Retail Offer

Summary by AI BETAClose X

CRISM Therapeutics Corporation has successfully raised gross proceeds of £59,610 through a retail offer of 662,332 shares at 9 pence per share. These funds, combined with those from a prior placing, will support the company's MHRA-approved Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma patients, with patient dosing expected in Q1 2026. The new Retail Offer Shares will be admitted to trading on the London Stock Exchange around December 16, 2025, bringing the total issued share capital to 51,735,266 ordinary shares.

Disclaimer*

UK 100

Latest directors dealings